Statement of Ownership (sc 13g)
February 13 2020 - 6:05AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13G
INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)
(Amendment No. _____)*
RAPT Therapeutics, Inc.
(Name of
Issuer)
Common Stock
(Title of
Class of Securities)
75382E109
(CUSIP Number)
December 31, 2019
(Date of
Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
*The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
(Continued on following pages)
Page 1
of 9
Exhibit Index on Page 8
CUSIP #75382E109
|
Page 2 of 9
|
1
|
NAME
OF REPORTING PERSONS
Kleiner Perkins Caufield & Byers XV, LLC (“KPCB XV”)
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
¨
(b) x
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
3,444,199 shares, except that KPCB XV Associates, LLC (“Associates”), the managing member of KPCB XV, may be deemed to have sole power to vote these shares.
|
|
6
|
SHARED VOTING POWER
See response to row 5.
|
|
7
|
SOLE DISPOSITIVE POWER
3,444,199 shares, except that Associates, the managing member of KPCB XV, may be deemed to have sole power to dispose of these shares.
|
|
8
|
SHARED DISPOSITIVE POWER
See response to row 7.
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
|
3,444,199
|
10
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
¨
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
|
15.8%
|
12
|
TYPE OF REPORTING PERSON
|
OO
|
CUSIP #75382E109
|
Page 3 of 9
|
1
|
NAME
OF REPORTING PERSONS
KPCB XV
Founders Fund, LLC (“KPCB XV Founders”)
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
¨
(b) x
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
102,864 shares, except that Associates, the managing member of KPCB XV Founders, may be deemed to have sole power to vote these shares.
|
|
6
|
SHARED VOTING POWER
See response to row 5.
|
|
7
|
SOLE DISPOSITIVE POWER
102,864 shares, except that Associates, the managing member of KPCB XV Founders, may be deemed to have sole power to dispose of these shares.
|
|
8
|
SHARED DISPOSITIVE POWER
See response to row 7.
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON
|
102,864
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES
|
¨
|
11
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW 9
|
0.5%
|
12
|
TYPE OF REPORTING PERSON
|
OO
|
CUSIP #75382E109
|
Page 4 of 9
|
1
|
NAME
OF REPORTING PERSONS
KPCB XV
Associates, LLC
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ¨
(b) x
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
3,547,063 shares, of which 3,444,199 are directly owned by KPCB XV and 102,864 are directly owned by KPCB XV Founders. Associates, the managing member of KPCB XV and KPCB XV Founders, may be deemed to have sole power to vote these shares.
|
|
6
|
SHARED VOTING POWER
See response to row 5.
|
|
7
|
SOLE DISPOSITIVE POWER
3,547,063 shares, of which 3,444,199 are directly owned by KPCB XV and 102,864 are directly owned by KPCB XV Founders. Associates, the managing member of KPCB XV and KPCB XV Founders, may be deemed to have sole power to dispose of these shares.
|
|
8
|
SHARED DISPOSITIVE POWER
See response to row 7.
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH
REPORTING PERSON
|
3,547,063
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES
|
¨
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
|
16.3%
|
12
|
TYPE OF REPORTING PERSON
|
OO
|
CUSIP #75382E109
|
Page 5 of 9
|
ITEM 1(A).
|
NAME OF ISSUER
|
|
|
|
RAPT Therapeutics, Inc. (the “Issuer”)
|
ITEM 1(B).
|
ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
|
|
|
|
561 Eccles Avenue
|
|
South San Francisco, CA 94080
|
ITEM 2(A).
|
NAME OF PERSONS FILING
|
|
|
|
This Schedule is filed by Kleiner Perkins Caufield & Byers XV, LLC, a Delaware limited liability company, KPCB XV Founders
Fund, LLC, a Delaware limited liability company, and KPCB XV Associates, LLC, a Delaware limited liability company. The foregoing
entities are collectively referred to as the “Reporting Persons.”
|
ITEM 2(B).
|
ADDRESS OF PRINCIPAL OFFICE
|
The address for each of the Reporting Persons
is:
c/o Kleiner Perkins Caufield &
Byers
2750 Sand Hill Road
Menlo Park, California 94025
ITEM 2(C).
|
CITIZENSHIP
|
|
|
|
See Row 4 of cover page for each Reporting Person.
|
ITEM 2(D).
|
TITLE OF CLASS OF SECURITIES
Common Stock, $.0001 par value
|
ITEM 2(E).
|
CUSIP NUMBER
75382E109
|
ITEM 3.
|
If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check
whether the person filing is a:
Not applicable.
|
CUSIP #75382E109
|
Page 6 of 9
|
The following information with respect
to the ownership of the ordinary shares of the Issuer by the persons filing this Statement is provided as of December 31,
2019:
|
(a)
|
Amount beneficially owned:
See Row 9 of cover page for each Reporting Person.
|
|
(b)
|
Percent of Class:
See Row 11 of cover page for each Reporting Person.
|
|
(c)
|
Number of shares as to which such person has:
|
|
(i)
|
Sole power to vote or to direct the vote:
See Row 5 of cover page for each Reporting Person.
|
|
(ii)
|
Shared power to vote or to direct the vote:
|
See Row 6 of cover page for each
Reporting Person.
|
(iii)
|
Sole power to dispose or to direct the disposition of:
|
See Row 7 of cover page for each
Reporting Person.
|
(iv)
|
Shared power to dispose or to direct the disposition of:
See Row 8 of cover page for each Reporting Person.
|
|
ITEM 5.
|
OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not applicable.
|
|
ITEM 6.
|
OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Under certain circumstances set forth in the limited liability company agreements of the Reporting Persons, the members of such
entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned
by each such entity of which they are a member.
|
|
ITEM 7.
|
IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY
Not applicable.
|
|
ITEM 8.
|
IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not applicable.
|
|
ITEM 9.
|
NOTICE OF DISSOLUTION OF GROUP.
Not applicable.
|
|
ITEM 10.
|
CERTIFICATION.
Not applicable.
|
CUSIP #75382E109
|
Page 7 of 9
|
SIGNATURES
After reasonable inquiry and to the best of
my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 12, 2020
|
|
|
|
|
KLEINER PERKINS CAUFIELD & BYERS XV, LLC, a
Delaware limited liability company
|
|
|
|
By: KPCB XV ASSOCIATES, LLC, a Delaware limited
liability company, its managing member
|
|
|
|
By:
|
/s/ Susan Biglieri
|
|
|
Susan Biglieri
|
|
|
Chief Financial Officer
|
|
|
|
|
|
KPCB XV FOUNDERS FUND, LLC, a Delaware limited
liability company
|
|
|
|
By: KPCB XV ASSOCIATES, LLC, a Delaware limited
liability company, its managing member
|
|
|
|
By:
|
/s/ Susan Biglieri
|
|
|
Susan Biglieri
|
|
|
Chief Financial Officer
|
|
|
|
|
|
KPCB XV ASSOCIATES, LLC, a Delaware limited
liability company
|
|
|
|
By:
|
/s/ Susan Biglieri
|
|
|
Susan Biglieri
|
|
|
Chief Financial Officer
|
CUSIP #75382E109
|
Page 8 of 9
|
EXHIBIT INDEX
|
Found on
Sequentially
|
Exhibit
|
Numbered Page
|
Exhibit A: Agreement of Joint Filing
|
9
|
CUSIP #75382E109
|
Page 9 of 9
|
exhibit A
Agreement of Joint Filing
The undersigned hereby
agree that a single Schedule 13G (or any amendment thereto) relating to the common stock of the Issuer shall be filed on behalf
of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.
|
|
Date: February 12, 2020
|
|
|
|
|
KLEINER PERKINS CAUFIELD & BYERS XV, LLC, a
Delaware limited liability company
|
|
|
|
By: KPCB XV ASSOCIATES, LLC, a Delaware limited
liability company, its managing member
|
|
|
|
By:
|
/s/ Susan Biglieri
|
|
|
Susan Biglieri
|
|
|
Chief Financial Officer
|
|
|
|
|
|
KPCB XV FOUNDERS FUND, LLC, a Delaware limited
liability company
|
|
|
|
By: KPCB XV ASSOCIATES, LLC, a Delaware limited
liability company, its managing member
|
|
|
|
By:
|
/s/ Susan Biglieri
|
|
|
Susan Biglieri
|
|
|
Chief Financial Officer
|
|
|
|
|
|
KPCB XV ASSOCIATES, LLC, a Delaware limited
liability company
|
|
|
|
By:
|
/s/ Susan
Biglieri
|
|
|
Susan Biglieri
|
|
|
Chief Financial Officer
|
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Apr 2023 to Apr 2024